Literature DB >> 26660426

Essential control of early B-cell development by Mef2 transcription factors.

Julia Herglotz1, Ludmilla Unrau1, Friderike Hauschildt1, Meike Fischer1, Neele Kriebitzsch1, Malik Alawi2, Daniela Indenbirken3, Michael Spohn3, Ursula Müller1, Marion Ziegler1, Wolfgang Schuh4, Hans-Martin Jäck4, Carol Stocking1.   

Abstract

The sequential activation of distinct developmental gene networks governs the ultimate identity of a cell, but the mechanisms involved in initiating downstream programs are incompletely understood. The pre-B-cell receptor (pre-BCR) is an important checkpoint of B-cell development and is essential for a pre-B cell to traverse into an immature B cell. Here, we show that activation of myocyte enhancer factor 2 (Mef2) transcription factors (TFs) by the pre-BCR is necessary for initiating the subsequent genetic network. We demonstrate that B-cell development is blocked at the pre-B-cell stage in mice deficient for Mef2c and Mef2d TFs and that pre-BCR signaling enhances the transcriptional activity of Mef2c/d through phosphorylation by the Erk5 mitogen-activating kinase. This activation is instrumental in inducing Krüppel-like factor 2 and several immediate early genes of the AP1 and Egr family. Finally, we show that Mef2 proteins cooperate with the products of their target genes (Irf4 and Egr2) to induce secondary waves of transcriptional regulation. Our findings uncover a novel role for Mef2c/d in coordinating the transcriptional network that promotes early B-cell development.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26660426     DOI: 10.1182/blood-2015-04-643270

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.

Authors:  Ines C Angerer; Michael Hecker; Dirk Koczan; Luisa Roch; Jörg Friess; Annelen Rüge; Brit Fitzner; Nina Boxberger; Ina Schröder; Kristin Flechtner; Hans-Jürgen Thiesen; Alexander Winkelmann; Stefanie Meister; Uwe K Zettl
Journal:  CNS Neurosci Ther       Date:  2018-01-03       Impact factor: 5.243

2.  EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.

Authors:  E Young; D Noerenberg; L Mansouri; V Ljungström; M Frick; L-A Sutton; S J Blakemore; J Galan-Sousa; K Plevova; P Baliakas; D Rossi; R Clifford; D Roos-Weil; V Navrkalova; B Dörken; C A Schmitt; K E Smedby; G Juliusson; B Giacopelli; J S Blachly; C Belessi; P Panagiotidis; N Chiorazzi; F Davi; A W Langerak; D Oscier; A Schuh; G Gaidano; P Ghia; W Xu; L Fan; O A Bernard; F Nguyen-Khac; L Rassenti; J Li; T J Kipps; K Stamatopoulos; S Pospisilova; T Zenz; C C Oakes; J C Strefford; R Rosenquist; F Damm
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

3.  MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.

Authors:  Fiona C Brown; Eric Still; Richard P Koche; Christina Y Yim; Sumiko Takao; Paolo Cifani; Casie Reed; Shehana Gunasekera; Scott B Ficarro; Peter Romanienko; Willie Mark; Craig McCarthy; Elisa de Stanchina; Mithat Gonen; Venkatraman Seshan; Patrick Bhola; Conor O'Donnell; Barbara Spitzer; Crystal Stutzke; Vincent-Philippe Lavallée; Josée Hébert; Andrei V Krivtsov; Ari Melnick; Elisabeth M Paietta; Martin S Tallman; Anthony Letai; Guy Sauvageau; Gayle Pouliot; Ross Levine; Jarrod A Marto; Scott A Armstrong; Alex Kentsis
Journal:  Cancer Discov       Date:  2018-02-05       Impact factor: 39.397

4.  SORBS2, mediated by MEF2D, suppresses the metastasis of human hepatocellular carcinoma by inhibitiing the c-Abl-ERK signaling pathway.

Authors:  Bin Yan; Zhiyong Peng; Chungen Xing
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

5.  MEF2D Fusions Drive Oncogenic Pre-BCR Signaling in B-ALL.

Authors:  Teresa Sadras; Markus Müschen
Journal:  Blood Cancer Discov       Date:  2020-06-22

6.  Molecular Mechanisms of ARID5B-Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia.

Authors:  Xujie Zhao; Maoxiang Qian; Charnise Goodings; Yang Zhang; Wenjian Yang; Ping Wang; Beisi Xu; Cheng Tian; Ching-Hon Pui; Stephen P Hunger; Elizabeth A Raetz; Meenakshi Devidas; Mary V Relling; Mignon L Loh; Daniel Savic; Chunliang Li; Jun J Yang
Journal:  J Natl Cancer Inst       Date:  2022-09-09       Impact factor: 11.816

7.  Enhancer jungles establish robust tissue-specific regulatory control in the human genome.

Authors:  Shan Li; Ivan Ovcharenko
Journal:  Genomics       Date:  2019-12-27       Impact factor: 5.736

8.  MEF2 (Myocyte Enhancer Factor 2) Is Essential for Endothelial Homeostasis and the Atheroprotective Gene Expression Program.

Authors:  Yao Wei Lu; Nina Martino; Brennan D Gerlach; John M Lamar; Peter A Vincent; Alejandro P Adam; John J Schwarz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-01-07       Impact factor: 8.311

9.  MEF2A transcriptionally upregulates the expression of ZEB2 and CTNNB1 in colorectal cancer to promote tumor progression.

Authors:  Qing Xiao; Yaqi Gan; Yimin Li; Lili Fan; Jiaqi Liu; Pengyan Lu; Jiaxin Liu; Aoao Chen; Guang Shu; Gang Yin
Journal:  Oncogene       Date:  2021-04-16       Impact factor: 9.867

10.  A Biological Circuit Involving Mef2c, Mef2d, and Hdac9 Controls the Immunosuppressive Functions of CD4+Foxp3+ T-Regulatory Cells.

Authors:  Eros Di Giorgio; Liqing Wang; Yan Xiong; Lanette M Christensen; Tatiana Akimova; Rongxiang Han; Arabinda Samanta; Matteo Trevisanut; Claudio Brancolini; Ulf H Beier; Wayne W Hancock
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.